News

Apotex recalling blood pressure med made at banned plant in India

Canadian generics maker Apotex is recalling tens of thousands of bottles of a blood pressure medication manufactured at a plant in India which the FDA banned after discovering it had been faking test data for years.  

Recipharm picks up two more plants, this time in Portugal

Sweden's Recipharm is expanding its production footprint for the second time this year, with a €112.3 million ($140 million) cash and stock deal to buy Portuguese contract manufacturer and developer Lusomedicamenta Sociedade Técnica Farmacêutica.

Japan's largest CMO, Bushu, gets new private equity owner

In a deal valued at more than $660 million, Baring Private Equity Asia showed up Monday as the buyer of a Japanese CMO and Tokio Marine Capital as the seller.

Getting more FDA inspectors in China on Hamburg's agenda for trip to China

For nearly two years, efforts by the FDA to expand its oversight of Chinese pharmaceuticals manufactured for the U.S. market have been thwarted, an issue FDA Commissioner Margaret Hamburg hopes to resolve during a visit there this week to meet with Chinese and other global regulators.

Bristol-Myers to build $900M biologics plant in Ireland

Bristol-Myers Squibb, having already expanded its U.S. production to make more biologics with its facility in Devens, MA, will now erect its twin in Ireland, a 320,000-square-foot facility adjacent to a bulk manufacturing facility in Dublin.

Former top execs at Ranbaxy U.S. open consulting business

Ranbaxy's top U.S. execs were seen as pivotal in the company getting approval to move production of a generic of Novartis' blockbuster Diovan from a banned plant in India to Ranbaxy's New Jersey facility. But a handful of them resigned last month, and now they intend to use that experience helping other drugmakers make it through the FDA's tough maze of regulations, and to negotiate with payers.

Sun's deal to buy Ranbaxy faces delays

The owner and top executive of India's Sun Pharmaceutical Industries has pledged that the first thing he will do when his deal to buy Ranbaxy Laboratories closes is make the needed investments in Ranbaxy's manufacturing plants to bring them in line with the FDA's expectations. But those improvements will have to wait awhile yet.

Spain's Exeltis gets two plants in Turkey with deal for Embil

The biotech arm of Spain's Grupo Chemo earlier this year bought a contract manufacturer in Spain specializing in monoclonal antibodies as part of its ambitions to produce biosimilars. Now its pharma division will get two manufacturing plants in Turkey and a portfolio of products with an acquisition there.

Neopharma to build plant in Saudi Arabia

Neopharma, based in the United Arab Emirates, will build a plant in a new industrial city being developed in the south of the country. B.R. Shetty, who controls both Neopharma and New Medical Center Group of Companies, has pledged to spend 1 billion Saudi riyals ($266.5 million) to build both a drug manufacturing facility and a hospital in Jarzan City.

Consort's Aesica buyout sets it up to jointly develop drugs and delivery devices

With its buyout of Aesica complete, the U.K's Consort is ready to fill more drug delivery devices, as well as an opportunity in the market. A specialist in developing inhalers, its Bespak device business will now be able to help companies take a drug from API manufacture, through joint development of the drug and device, and then onto the market.

Police probe wholesalers for selling subsidized drugs outside of Spain

In what is shaping into a major pharma supply chain scandal in Spain, investigators have accused one of the country's largest wholesalers of diverting millions of euros' worth of drugs subsidized by the government to the black market.

Aurobindo buys supplement maker Natrol out of bankruptcy

Aurobindo will pick up vitamin and supplement maker Natrol for $132.5 million, which it bid for the company in a Chapter 11 bankruptcy auction, the Wall Street Journal reports.

UPDATE: Cadila Pharmaceuticals API plant slapped for faulty follow-up on stinking APIs

When India's Cadila Pharmaceuticals got complaints from customers about some of its APIs smelling bad, the drugmaker decided the odor stemmed from an impurity, so it tweaked the manufacturing process. The problem, according to the FDA, is that the plant never conducted an investigation to determine whether the impurity was in fact the cause, so the company never knew whether it had really resolved the cause of the stench.

Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls

Dr. Reddy's Laboratories, along with U.S. drugmaker Endo Health Solutions, will benefit from the ongoing manufacturing problems at Ranbaxy Laboratories. The FDA has approved their generics of Roche's antiviral Valcyte, a drug Ranbaxy had an 180-day exclusive for, but lost because of regulatory issues.

Plant power outage zaps the juice from AMRI's earnings

Earlier this year, AMRI paid $110 million for injectable drug specialist Oso Biopharmaceuticals Manufacturing, expecting to make some extra money in its contract manufacturing operations. Instead, a power loss at that company's facility in New Mexico was a big factor in it reporting a loss in the last quarter.

Dendreon, done in by expensive, complex manufacturing, files for bankruptcy

A couple of years ago, Dendreon sold off a manufacturing plant to Novartis for $40 million-plus to raise some quick cash. Now, someone can pick up its two remaining manufacturing facilities, a logistics center and headquarters in Seattle and its one-time promising drug, Provenge, for as little as $275 million.

Fresenius expansion plans in Russia sidelined by political turmoil

Planning to expand its production capacity in Russia and the former Soviet Republic, Germany's Fresenius Kabi agreed this year to partner up with Binnopharm, a Moscow-based drugmaker that has two manufacturing facilities making IV drugs, infusion solutions and active pharmaceutical ingredients, not unlike Fresenius. But the political situation in Russia has made that too difficult, so Fresenius and Binnopharm are exploring other ways to work together.

Two more guilty pleas in spectacular burglary of Lilly warehouse

Two more men have pleaded guilty to the daring burglary of drugs from an Eli Lilly warehouse in Connecticut in 2010. Yosmany Nunez and Alexander Marquez, both of Florida, pleaded guilty this week, according to NBC.

Roche to invest $465M in new plant in China

While other drugmakers have been putting up drug manufacturing facilities left and right in China, Roche has been more conservative in its approach there. Now it will invest significantly to build a manufacturing facility to make lab tests.

Valeant labeling snafu affects Sanofi's Aplenzin, as well as Valeant's vaseretic

The 206,000 bottles of blood pressure medication vaseretic that Valeant has been recalling is not the only product affected by a packaging snafu that resulted in outdated package inserts. The drugmaker has also been retrieving 19 lots of the antidepressant Aplenzin that it makes for Sanofi.